Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
Study D9108C00001 (COAST) is a Phase 2, open‐label, multicenter, randomized multidrug platform study assessing the efficacy and safety of durvalumab alone vs durvalumab in combination with novel agents in subjects with locally advanced, unresectable, Stage III non‐small cell lung cancer (NSCLC).
Epistemonikos ID: 22b3870dc7abd899c6baa09149fc9defe67ac4c7
First added on: May 22, 2024